Last updated: April 25, 2026
Germany Patent DE60005819: Scope, Claims, and Landscape
What is DE60005819 and what does it cover?
DE60005819 is a German publication that corresponds to an international patent application filed under the PCT route. The “DE” publication number format and the “600…” sequence align with a WO/EP-origin application that entered the German national/regional phase and was published in Germany under the “DE” designation.
Scope characterization (high-level): DE60005819 covers a specific pharmaceutical invention defined in the claims. The scope is determined by the claim language (composition, formulation, method of treatment, or method of manufacturing) and any claim dependencies that narrow coverage by specifying additional parameters such as active ingredient identity, dosage range, patient population, route of administration, excipient system, or process steps.
Core point for landscape use: Without the claim text and description text, an exact claim-by-claim technical mapping (active ingredient, salt form, indications, dose regimens, and administration route) cannot be produced in a way that satisfies patent-analyst standards for precision and enforceability.
What is the claim structure and how do dependencies affect enforcement?
Patent claim sets typically include:
- Independent claims that define the broadest subject matter using the minimum required structural/functional elements.
- Dependent claims that narrow the independent claim by adding specific limitations (example: a defined dosage, a defined formulation component, a defined patient group, or a defined sequence of steps).
Scope impact in enforcement:
- Courts and examiners interpret claim meaning through the independent claim first, then apply dependent limitations to determine the actual protected embodiments.
- If DE60005819 includes Markush-style alternative elements (common in pharma), each alternative can operate as a separate infringement pathway depending on how the alternatives are drafted.
- If DE60005819 includes product-by-process wording, infringement often turns on product characteristics that the process supposedly yields, not just whether a competitor uses the same manufacturing steps.
What claim elements determine freedom-to-operate (FTO) risk in Germany?
For drug patents, the highest FTO sensitivity is usually in these elements:
- Active ingredient identity: the specific chemical entity, stereoisomer, or salt.
- Formulation definition: salts, polymorph identifiers, particle size, excipient system, release profile (IR, ER, SR).
- Indication and therapeutic use: method-of-treatment claims are constrained by the patient group and disease definition.
- Dosage regimen: dose amount per unit and dosing interval.
- Route of administration: oral vs parenteral often changes overlap with generic labeling and prescribing patterns.
- Method of manufacturing steps: critical where the generic’s process can be controlled only indirectly.
Because DE60005819’s actual claim language is not provided in the record accessible here, no reliable mapping to those elements can be stated.
Claim-Driven Landscape: How to assess DE60005819 against competing IP
What infringement theories typically arise for a German pharma claim set?
For DE-origin pharma families, enforcement patterns in Germany commonly map to three theories:
- Product claims (composition/formulation)
- Infringement generally requires the accused product to fall within all claim limitations, including specific formulation attributes.
- Method-of-treatment claims
- Infringement can turn on prescribing practice and evidence that the medical use matches the claim steps and patient/disease criteria.
- Use claims (second medical use)
- Overlap depends on the claimed therapeutic indication and whether the competitor’s labeling and clinical practice fall within the use definition.
Without DE60005819’s exact claim categories, the landscape can only be described structurally, not applied to concrete competitors.
How does the German procedural framework affect enforceability and claim construction?
Germany’s enforcement and validity outcomes are driven by:
- Written claim construction: German courts interpret claim scope by claim language, description, and prosecution history.
- Technical equivalence: depends on the claim framing; narrow claim definitions reduce equivalence coverage.
- Validity challenges: novelty, inventive step, and clarity.
- Secondary considerations: sometimes become relevant in inventive-step disputes, especially when claim language follows standard technical practice.
A precise landscape requires the claim terms and the family’s examination history, which are not present here.
Family and timeline requirements for a defensible landscape
A “patent landscape” for a German drug patent should track:
- Priority date(s)
- Publication dates (WO/EP/DE)
- Grant status in Germany (granted vs pending; if granted, publication of grant and amended claims)
- Opposition events (if any) and outcomes
- Legal status (in force, lapsed, terminated)
- Exclusivity periods (supplementary protection certificates where applicable in Germany)
- Terminal disclaimer or partial priority issues
- Related family members (continuations/divisionals, related WO/EP filings)
None of this can be populated accurately for DE60005819 without the underlying bibliographic and legal-status record for the specific German file.
Key takeaways
- DE60005819 is a German-published patent document tied to a broader (WO/EP-origin) filing pathway, and its enforceable scope depends on its exact claim language.
- A claim-by-claim scope and infringement/invalidity mapping cannot be completed to the standard required for business decisions without the claim text, bibliographic data, and legal status.
- The dominant levers for landscape risk in Germany are claim category (product vs method of treatment), formulation/parameter specificity, therapeutic use wording, dosage and regimen definitions, and any process-product constraints.
FAQs
-
What determines DE60005819’s protective scope in Germany?
The independent claim language and any dependent claim limitations, interpreted in light of the description and the prosecution history.
-
What makes a pharma patent claim high-risk for generics in Germany?
Narrowly defined product attributes (formulation/polymorph/release profile), tight method-of-treatment conditions (patient group and disease definition), and specific dosing regimens.
-
How do dependent claims change infringement analysis?
Each dependent claim adds specific limitations; an accused product or method must satisfy all limitations of the asserted claim, not the independent claim alone.
-
Do method-of-treatment claims require evidence of actual prescribing?
Typically, enforcement depends on demonstrating that the claimed medical use is carried out in the real world consistent with the claim steps and patient/disease criteria.
-
What else should a landscape include beyond the patent text?
Germany-specific legal status, grant and opposition history, family members with related claims, and any supplementary protection certificate effect where applicable.
References
No sources were retrievable or provided in this session for DE60005819’s bibliographic record, claim set, or legal status, so no numbered APA citations can be generated without fabricating data.
